Parkinson’s Disease and Stem Cell Therapy in Thailand

Parkinson’s disease has a clearer biological target than almost any other neurological condition: a specific population of dopamine-producing cells is lost. That has made it a focus of cell therapy research for forty years. Stem cell therapy for Parkinson’s disease now has a randomised trial behind it, and separating what that trial tested from what clinics sell is the point of this page.

The randomised trial

Allogeneic bone marrow-derived cells have been tested in a randomised trial — Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson’s Disease: A Randomized Trial.

Secondary analysis from the same programme looked at effects outside the brain — Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial.

A randomised trial in a progressive neurological condition is a serious piece of work, and its existence is why this page is graded above the other neurological pages here. Ask any clinic quoting it what the primary endpoint was and whether it was met.

Two completely different research traditions

The older tradition transplants tissue capable of producing dopamine directly into the brain, surgically, in the hope of replacing lost cells. A review covers that history — Parkinson’s disease: fetal cell or stem cell-derived treatments.

That work is decades old, used fetal tissue, produced some genuine long-term responders, and also produced graft-induced dyskinesias severe enough to halt programmes. It is surgery inside the brain, with all that implies.

The newer tradition infuses mesenchymal cells intravenously and hopes for an anti-inflammatory or supportive effect. These are not versions of the same treatment. One attempts cell replacement; the other does not attempt it and could not achieve it.

HSCT versus MSC infusion covers the same category confusion in a different setting.

Why the placebo problem here is unusually severe

Parkinson’s has the strongest documented placebo response of any condition in neurology. Dopamine release has been measured in the brains of patients given placebo, which means the placebo effect here is not merely reported — it is biochemical.

That has real consequences. Sham-surgery-controlled trials in Parkinson’s have repeatedly shown substantial improvement in the sham group, and several open-label treatments that looked promising did not survive a controlled comparison.

Any uncontrolled treatment for this condition will produce improved patients, improved videos, and grateful testimonials. None of that distinguishes an active treatment from an inactive one.

What existing treatment already achieves

Levodopa remains highly effective for motor symptoms and has been for over half a century. Most people respond well for years, and dose adjustment by a movement disorder specialist makes a considerable difference.

Deep brain stimulation has strong randomised evidence for selected patients with motor fluctuations, and is available in Thailand and elsewhere.

Someone considering an infusion should have exhausted proper optimisation of these first. That is not a delaying tactic; it is where the demonstrated benefit is.

What is not affected by any of this

The non-motor symptoms — constipation, sleep disturbance, loss of smell, mood changes, and cognitive change in later disease — often affect quality of life more than tremor does.

They also progress on their own timeline and are not addressed by dopamine replacement or by anything in the cell therapy literature.

A treatment plan that ignores them is incomplete regardless of what else it contains.

Route of delivery

Intravenous infusion is what is most commonly offered. Most infused cells are trapped in the lungs on first pass and very few reach the brain, which is a real constraint on any claim about brain effects.

Intrathecal delivery into spinal fluid is used in some research protocols and is considerably more invasive, with its own risks including headache, infection and bleeding.

Intracerebral delivery is neurosurgery. If someone describes an infusion as though it delivers cells into the brain, that is worth pressing on. Mesenchymal stem cell therapy covers what is known about where infused cells go.

The dyskinesia lesson

The fetal tissue programmes of the 1990s are the most instructive episode in this field, and they are almost never mentioned by clinics selling cell treatment for Parkinson’s.

Two sham-controlled trials were run. Neither met its primary endpoint overall, though younger patients did better in one. More significantly, a proportion of transplanted patients developed involuntary movements that persisted after their medication was withdrawn — dyskinesias caused by the graft itself rather than by the drugs.

Those movements were disabling in some cases and could not be reversed, because the graft could not be removed. That is the defining risk of putting cells into a brain: whatever they do, they keep doing.

The field responded seriously — refining cell types, purity and placement, and moving to carefully monitored trials. That response is the reason to take current research seriously and the reason to treat brain delivery outside a trial as unjustifiable.

Realistic expectations

Possible effects on some symptoms, on the basis of one randomised trial, with the size and durability of any effect still being established.

No basis for expecting lost dopamine neurons to be replaced by an intravenous infusion, and no published trial claiming it.

Progression continues. A treatment that does not stop progression may still be worth having if it helps symptoms, but those are different claims and should be presented as such.

Risks

Infusion reactions and transient fever, as elsewhere.

For intrathecal delivery, the specific risks of that route, which are greater and should be spelled out rather than mentioned in passing.

The cost of hope misdirected. Travelling for an unproven treatment during the years when established treatment works well is a real loss, and it is the risk least often discussed. Adverse events covers documented physical harms.

Questions worth asking

• Which trial supports this, and what did it find?
• Is this an infusion, and how many cells are expected to reach the brain?
• Has my medication been optimised by a movement disorder specialist?
• Have I been assessed for deep brain stimulation?
• How will any effect be measured, and by whom?

Ischaemic stroke and multiple sclerosis cover neighbouring neurological evidence, and the evidence levels explain this grading.

Frequently asked questions

Requesting a medical evaluation

Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.

Message us on WhatsApp

This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.